FAP-targeted CAR T-cell therapy: A promising approach for the treatment of Peyronie’s disease

Abstract

Peyronie’s disease is a fibro-inflammatory disease of penile connective tissue. Fibrotic plaque formed in Peyronie's disease can cause penile curvature disorders, anxiety disorders, and disruption of sexual life. Medical and surgical regimens are available to treat Peyronie's disease. However, current pharmacological treatment modalities are ineffective and may not prevent recurrences. Tissue losses and recurrences may occur in Peyronie's surgery performed for treatment. This situation creates the need for new-generation therapeutic agents. This article hypothesized how adoptive cell therapy with CAR T-cells, a popular and effective methodology, can be used to treat Peyronie's disease. Our hypothesis is centered around the development of a T cell equipped with a chimeric antigen receptor specifically designed to target FAP, which serves as an indicator of activated fibroblasts. We think it will be a promising therapy model for Peyronie's disease in the future because adoptive cell therapy can prevent recurrences because it takes place in the body for a long time and can reduce plaque before fibrotic tissue grows.